Bactiguard Holding AB (publ) (BACTI-B.ST)
SEK 37.2
(-2.11%)
SEK 37.2
(-2.11%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 203.99 Million SEK | -9.85% |
| 2022 | 223.56 Million SEK | 31.9% |
| 2021 | 169.48 Million SEK | -1.64% |
| 2020 | 172.31 Million SEK | -6.85% |
| 2019 | 184.98 Million SEK | 23.24% |
| 2018 | 150.09 Million SEK | 1.79% |
| 2017 | 147.45 Million SEK | 24.19% |
| 2016 | 118.73 Million SEK | -9.65% |
| 2015 | 131.42 Million SEK | 20.52% |
| 2014 | 109.04 Million SEK | -13.96% |
| 2013 | 126.73 Million SEK | -1.76% |
| 2012 | 129 Million SEK | 2843.98% |
| 2011 | 4.38 Million SEK | -96.27% |
| 2010 | 117.51 Million SEK | -7.48% |
| 2009 | 127.01 Million SEK | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q3 | 73.93 Million SEK | 28.91% |
| 2024 Q1 | 53.92 Million SEK | -4.13% |
| 2024 Q2 | 57.35 Million SEK | 6.36% |
| 2023 Q4 | 56.25 Million SEK | 13.67% |
| 2023 FY | 201.54 Million SEK | -9.85% |
| 2023 Q1 | 61.16 Million SEK | 44.8% |
| 2023 Q2 | 51.19 Million SEK | -16.29% |
| 2023 Q3 | 49.48 Million SEK | -3.34% |
| 2022 Q3 | 66.18 Million SEK | 10.43% |
| 2022 Q4 | 42.23 Million SEK | -36.18% |
| 2022 FY | 223.56 Million SEK | 31.9% |
| 2022 Q1 | 55.2 Million SEK | 51.28% |
| 2022 Q2 | 59.93 Million SEK | 8.57% |
| 2021 Q1 | 41.78 Million SEK | -0.16% |
| 2021 Q3 | 45.19 Million SEK | -1.78% |
| 2021 Q4 | 36.48 Million SEK | -19.27% |
| 2021 FY | 169.48 Million SEK | -1.64% |
| 2021 Q2 | 46.01 Million SEK | 10.14% |
| 2020 Q2 | 48.21 Million SEK | 0.22% |
| 2020 Q1 | 48.1 Million SEK | -1.45% |
| 2020 FY | 172.31 Million SEK | -6.85% |
| 2020 Q3 | 34.15 Million SEK | -29.16% |
| 2020 Q4 | 41.85 Million SEK | 22.55% |
| 2019 FY | 184.98 Million SEK | 23.24% |
| 2019 Q4 | 48.81 Million SEK | -27.13% |
| 2019 Q3 | 66.98 Million SEK | 96.6% |
| 2019 Q2 | 34.07 Million SEK | -2.97% |
| 2019 Q1 | 35.11 Million SEK | 20.78% |
| 2018 Q3 | 35.69 Million SEK | -31.85% |
| 2018 Q4 | 29.07 Million SEK | -18.54% |
| 2018 FY | 150.09 Million SEK | 1.79% |
| 2018 Q1 | 32.95 Million SEK | -6.3% |
| 2018 Q2 | 52.37 Million SEK | 58.9% |
| 2017 Q4 | 35.17 Million SEK | 1.1% |
| 2017 Q3 | 34.79 Million SEK | -4.59% |
| 2017 FY | 147.45 Million SEK | 24.19% |
| 2017 Q2 | 36.46 Million SEK | -11.12% |
| 2017 Q1 | 41.02 Million SEK | 71.02% |
| 2016 Q3 | 34.93 Million SEK | 3.33% |
| 2016 Q4 | 23.98 Million SEK | -31.33% |
| 2016 Q1 | 26 Million SEK | 93.98% |
| 2016 FY | 118.73 Million SEK | -9.65% |
| 2016 Q2 | 33.8 Million SEK | 29.99% |
| 2015 Q3 | 61.44 Million SEK | 121.56% |
| 2015 Q1 | 28.83 Million SEK | 89.06% |
| 2015 FY | 131.42 Million SEK | 20.52% |
| 2015 Q2 | 27.73 Million SEK | -3.82% |
| 2015 Q4 | 13.4 Million SEK | -78.18% |
| 2014 Q2 | 31.23 Million SEK | -9.46% |
| 2014 Q4 | 15.25 Million SEK | -45.65% |
| 2014 FY | 109.04 Million SEK | -13.96% |
| 2014 Q3 | 28.05 Million SEK | -10.17% |
| 2014 Q1 | 34.5 Million SEK | -20.79% |
| 2013 Q3 | 32.54 Million SEK | 46.99% |
| 2013 Q4 | 43.55 Million SEK | 33.83% |
| 2013 Q1 | 28.49 Million SEK | -0.24% |
| 2013 Q2 | 22.14 Million SEK | -22.28% |
| 2013 FY | 126.73 Million SEK | -1.76% |
| 2012 Q2 | 20.28 Million SEK | 0.0% |
| 2012 FY | 129 Million SEK | 2843.98% |
| 2012 Q4 | 28.55 Million SEK | 10.93% |
| 2012 Q3 | 25.74 Million SEK | 26.94% |
| 2011 Q4 | - SEK | 0.0% |
| 2011 FY | 4.38 Million SEK | -96.27% |
| 2010 FY | 117.51 Million SEK | -7.48% |
| 2009 FY | 127.01 Million SEK | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Acarix AB (publ) | 6.24 Million SEK | -3168.547% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 85.143% |
| ADDvise Group AB (publ) | 1.37 Billion SEK | 85.143% |
| Arcoma AB | 163.01 Million SEK | -25.136% |
| BICO Group AB (publ) | 2.23 Billion SEK | 90.891% |
| Boule Diagnostics AB (publ) | 571.32 Million SEK | 64.296% |
| CellaVision AB (publ) | 677.29 Million SEK | 69.882% |
| Clinical Laserthermia Systems AB (publ) | 8.27 Million SEK | -2365.732% |
| Chordate Medical Holding AB (publ) | 976.28 Thousand SEK | -20794.599% |
| C-Rad AB (publ) | 424.61 Million SEK | 51.959% |
| Duearity AB (publ) | 1.65 Million SEK | -12233.132% |
| Dignitana AB (publ) | 86.06 Million SEK | -137.024% |
| Episurf Medical AB (publ) | 10.3 Million SEK | -1880.485% |
| Getinge AB (publ) | 31.82 Billion SEK | 99.359% |
| Scandinavian Real Heart AB (Publ) | - SEK | -Infinity% |
| Iconovo AB (publ) | 7.07 Million SEK | -2781.912% |
| Integrum AB (publ) | 104.11 Million SEK | -95.921% |
| Luxbright AB (publ) | 854.69 Thousand SEK | -23766.882% |
| Mentice AB (publ) | 273.61 Million SEK | 25.445% |
| OssDsign AB (publ) | 112.15 Million SEK | -81.879% |
| Paxman AB (publ) | 210.11 Million SEK | 2.916% |
| Promimic AB (publ) | 37.07 Million SEK | -450.283% |
| Qlife Holding AB (publ) | 244 Thousand SEK | -83502.459% |
| SciBase Holding AB (publ) | 23.24 Million SEK | -777.565% |
| ScandiDos AB (publ) | 60.42 Million SEK | -237.57% |
| Sectra AB (publ) | 2.96 Billion SEK | 93.117% |
| Sedana Medical AB (publ) | 153.86 Million SEK | -32.576% |
| Senzime AB (publ) | 35.75 Million SEK | -470.538% |
| SpectraCure AB (publ) | 318 Thousand SEK | -64047.799% |
| Stille AB | 294.89 Million SEK | 30.826% |
| Vitrolife AB (publ) | 3.51 Billion SEK | 94.192% |
| Xvivo Perfusion AB (publ) | 597.54 Million SEK | 65.862% |